262.93
1.89%
+4.119
Madrigal Pharmaceuticals Inc stock is currently priced at $262.93, with a 24-hour trading volume of 100.74K.
It has seen a +1.89% increased in the last 24 hours and a +3.72% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $254.4 pivot point. If it approaches the $264.0 resistance level, significant changes may occur.
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Madrigal Pharmaceuticals Inc (MDGL) Net Income 2023
MDGL net income (TTM) was -$373.63 million for the quarter ending December 31, 2023, a -26.50% decrease year-over-year.
Madrigal Pharmaceuticals Inc (MDGL) Cash Flow 2023
MDGL recorded a free cash flow (TTM) of -$325.71 million for the quarter ending December 31, 2023, a -44.71% decrease year-over-year.
Madrigal Pharmaceuticals Inc (MDGL) Earnings per Share 2023
MDGL earnings per share (TTM) was -$19.98 for the quarter ending December 31, 2023, a -15.96% decline year-over-year.
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock
The Motley Fool
This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy?
The Motley Fool
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
The Motley Fool
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
GlobeNewswire Inc.
Madrigal Pharmaceuticals Announces Proposed Public Offering
GlobeNewswire Inc.
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia. It is also developing MGL-3745, a THR-ß-selective small molecule that is in preclinical trials. The company has research, development, and commercialization agreement with Hoffmann-La Roche to develop, use, sell, offer for sale, and import various licensed products. Madrigal Pharmaceuticals, Inc. was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.
Cap:
|
Volume (24h):